PROJECTED IMPACT OF OMIDUBICEL ON RACIAL AND ETHNIC DISPARITIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT ACCESS AND OUTCOMES FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES IN THE US

USAMA GERGIS,¹ NANDITA KHERA,² MARIE LOUISE EDWARDS,³ YAN SONG,⁴ ROCHELLE SUN,⁴ RONIT SIMANTOV,⁵ SMITHA SIVARAMAN,⁵* ROCIO MANGHANI,⁵ JAMES SIGNOROVITCH² ¹Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; ²Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; ³Analysis Group Inc., New York, NY, USA; ⁴Analysis Group Inc., Boston, MA, USA; ⁵Gamida Cell Ltd., Boston, MA, USA; ¹Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; ⁴Analysis Group Inc., New York, NY, USA; ⁴Analysis Group Inc., Boston, MA, USA; ⁵Gamida Cell Ltd., Boston, MA, USA; ⁴Division of Hematology and Medical Oncology, Department of Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; ⁴Analysis Group Inc., Boston, MA, USA; ⁵Gamida Cell Ltd., Boston, MA, USA; ⁴Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; ⁴Division of Hematology and Medical Oncology, Department of Medical On *Presenting author

BACKGROUND

- The majority of patients with hematologic malignancies (HM) who are eligible for allogeneic hematopoietic cell transplant (allo-HCT) lack human leukocyte antigen (HLA)-matched related donors (MRD) and rely on donor registries to identify matchedor mismatched-unrelated donor (MUD, MMUD), or umbilical cord blood (UCB)¹
- The likelihood of finding a match in donor registries differs by race and contributes to racial disparities in health outcomes²
- Omidubicel, an advanced cell therapy for allo-HCT patients. demonstrated superior hematopoietic recovery and decreased early transplant-related mortality compared with standard UCB HCT in a phase III clinical trial (NCT02730299)
- More than 40% of patients in the trial were minorities, and consistent clinical benefit was demonstrated across race groups. Thus, access to omidubicel may reduce racial and ethnic health disparities for allo-HCT-eligible patients
- In this analysis, we hypothesized that access to omidubicel may reduce racial and ethnic health disparities for allo-HCT–eligible patients

OBJECTIVE

• To quantify the expected effects of access to omidubicel on health disparities in allo-HCT access and outcomes for patients with HM in the United States

METHODS

- A decision tree model was developed to project allo-HCT access and clinical outcomes in a hypothetical population of 10,000 allo-HCT-eligible patients in the US with HM lacking MRD (Figure 1)
- The model assigned patients to receive MUD/MMUD, haploidentical (HI), UCB transplant, or no transplant according to probabilities sourced from real-world evidence and based on assumptions^{2,3}
- A status quo scenario including 0% omidubicel use was treated as the reference case. Scenarios with omidubicel use of 10%, 15%, 20%, and 30% were modeled based on proportional reductions in use of other allo-HCT donor types or no transplant, drawing evenly among racial subgroups
- Weighted average outcomes, across transplant donor types. were calculated for the overall population and by race groups
- Studied outcomes were time to allo-HCT, 1-year nonrelapse mortality (NRM), and 1-year overall survival (OS)
- Average time to allo-HCT and NRM outcomes were modeled among patients receiving transplant in each scenario. 1-year OS was modeled in the entire patient cohort, inclusive of those not receiving a transplant
- Clinical inputs for each allo-HCT type were drawn from clinical trials,⁴⁻⁶ public data from the Center for International Blood and Marrow Transplant Research (CIBMTR),³ and published studies and assumptions (**Table 1**)⁷⁻¹¹
- The distribution of patients receiving each modeled transplant type was sourced from the CIBMTR and the US Department of Health and Human Services³
- Average time from establishment of transplant eligibility to transplant procedure was sourced from published studies and assumptions
- Efficacy for each transplant type was assumed to apply to all patients receiving the transplant-ie, differences in transplant efficacy by race were not considered

FIGURE 1. MODEL SCHEMA

Cohort

US allo-HCT–eligible patients with HM who are indicated for transplantation with omidubicel and for whom MRD are not available

The model considered the cohort overall and stratified by race/ethnicity:								
• White • Black	• Asian • Hispanic	• Other						

relapse mortality; OS: overall survival; UCB: umbilical cord blood; US: United State


TABLE 1. KEY CLINICAL INPUTS

	Omidubicel	MUD/MMUD	HI donor	UCB transplant	No transplant	Sources
Patients receiving each transplant option at status quo (%)	-	39.9	14.7	5.0	40.4	CIBMTR US HHS Data ³
Average time to transplant procedure (weeks)	4.0	15.1	4.3	3.7	-	Omidubicel: Assumption MUD/MMUD: Mayani 2020 ¹¹ HI: Ciurea 2018 ⁹ UCB: Gamida Cell Trial Data
1-year NRM (%)	15.4	23.7	24.1	28.6	-	Omidubicel: Gamida Cell Trial Data MUD/MMUD: Baker 2016 ⁷ HI: Baker 2016 ⁷ UCB: Gamida Cell Trial Data
1-year OS (%)	73.0	70.8	62.0	60.0	52.5	Omidubicel: Gamida Cell Trial Data MUD/MMUD: CIBMTR HI: Brunstein 2011 ⁵ UCB: Gamida Cell Trial Data No transplant: Lerch 2009, ⁸ Goldstone 2008 ⁶

CIBMTR: Center for International Blood and Marrow Transplant Research; HI: haploidentical; MUD: matched-unrelated donor; MMUD: mismatched-unrelated donor; NRM: non-relapse mortality: OS: overall survival; UCB: umbilical cord blood; US HHS: United States Department of Health and Human Services.

RESULTS

- In a modeled population of 10,000 patients for whom MRD were unavailable, 5956 (60%) were estimated to receive allo-HCT using current comparator donor sources (MUD, MMUD, HI, UCB) under the status quo scenario without omidubicel. 4044 patients (40%) in the status quo population did not receive allo-HCT
- received an allo-HCT
- Mean times from transplant assignment to transplant procedure and 1-year NRM were 11.5 weeks and 24%, respectively, among transplanted patients. Including those not transplanted, 1-year OS was 62% overall, ranging from 56% (Black) to 65% (White)
- Modeled increases in omidubicel use in eligible patients were associated with higher proportions of patients undergoing allo-HCT, decreased time to allo-HCT, decreased 1-year NRM, and increased 1-year OS. Improvements were greater among racial minorities but their results generally lagged behind those of White patients. In a scenario evaluating 20% omidubicel uptake:
- The proportion of Black patients receiving allo-HCT increased by 71%, with significant increases also noted in non-Black minorities (Asian [43%], Hispanic [30%], other [27%]), and a modest increase in White patients (5%) (**Figure 2**)
- Modeled time to allo-HCT improved 19% among all transplanted patients, with improvements ranging from 33% in Black patients to 16% in White patients (**Figure 3**)
- among Asian, Hispanic, and other racial or ethnic subgroups (**Figure 4**)
- 6% among Black and Asian patients (**Figure 5**)




Allo-HCT: allogeneic hematopoietic cell transplantation; HI: haploidentical; HM: hematologic malignancies; MRD: matched donor; MUD: matched-unrelated donor; MMUD: mismatched-unrelated donor; NRM: non-

53.			

- Among transplanted patients, 80% of White patients underwent allo-HCT, whereas only 40% of Hispanic, 32% of Asian, and 22% of Black patients

- Similarly, 1-year NRM decreased 11%, with a 9% reduction among White patients, 20% reduction among Black patients, and 14%–17% reductions

- 1-year OS increased by 4% in the overall population, including non-transplanted patients, with improvements ranging from 3% among White patients to



^aThe status quo scenario is defined as 0% omidubicel use. Allo-HCT: allogeneic hematopoietic cell transplantation






FIGURE 2. PROPORTION OF PATIENTS RECEIVING ALLO-HCT



FIGURE 4. PROPORTION OF TRANSPLANTED PATIENTS EXPERIENCING **1-YEAR NRM**



^aThe status quo scenario is defined as 0% omidubicel use. NRM: non-relapse mortality.



^aThe status quo scenario is defined as 0% omidubicel use. OS: overall survival.

FIGURE 5. PROPORTION OF PATIENTS ACHIEVING 1-YEAR OS

LIMITATIONS

- Utilization and outcomes data are from historic studies/registries/clinical trials and assumptions
- Projections are based on assumed levels of omidubicel uptake and translation of clinical trial results to real-world results
- The present study focused on racial disparities in finding suitable donor tissue for allo-HCT. Other possible contributors to inequity, such as differences in socioeconomic status, health insurance status. care-seeking challenges, or geographical hurdles should also be studied and addressed

CONCLUSIONS

- We project that omidubicel will extend access to allo-HCT-eligible HM patients, decrease time to transplant, and improve clinical outcomes
- The greatest benefits were seen among racial and ethnic groups with worse status quo outcomes
- Higher levels of modeled omidubicel uptake were associated with greater improvements in clinical outcomes and greater reductions in racial disparities

REFERENCES

- 1. Howard CA, et al. Biol Blood Marrow Transplant 2015;21:4–7.
- 2. Gragert L, et al. *N Engl J Med*. 2014;371:339–348.
- 3. Donor Registry Transplant Data. Last Updated: April 15, 2021. National Marrow Donor Program, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau.
- 4. Horwitz ME, et al. *Blood*. 2021;138:1429–1440.
- 5. Brunstein CG, et al. Blood. 2011;118:282–288.
- 6. Goldstone AH, et al. *Blood*. 2008;111:1827–1833.
- 7. Baker M, et al. *Biol Blood Marrow Transplant*. 2016;22: 2047-2055.
- 8. Lerch E, et al. Tumori. 2009;95:303-310.
- 9. Ciurea SO, et al. Blood Adv. 2018;2:2254-2261.
- 10. Lee SJ, et al. Blood. 2007;110:4576-4583.
- 11. Mayani H, et al. *Bone Marrow Transplant*. 2020;55:48–61.

DISCLOSURES

UG is an advisor or consultant for Astellas, Gamida Cell Ltd., Incyte, Jazz Pharmaceuticals, Mesoblast, and Novartis; reports honoraria from Kite. NK has no disclosures. MLE, YS, RSun, and JS are employees of Analysis Group Inc., which received consulting fees from Gamida Cell Ltd. for this research. RSimantov, SS, and RM are employees of Gamida Cell Ltd. This research was funded by Gamida Cell.

ACKNOWLEDGMENTS

Editorial support was provided by Evidence Scientific Solutions, and was funded by Gamida Cell.

